Laminins (abbreviated as LN) are part of a large family of extracellular matrix basal laminal glycoproteins and play important roles in cell adhesion, growth, communication and tumor metastasis. LN consists of alpha, beta and gamma polypeptide chains that are linked by disulfide bridges to form a characteristic asymmetric cross-structure that has been observed via electron microscopy. LN also binds to various components of the basal membrane and is hypothesized to link these components together. Cell surface receptors that are thought to play a role in LN-mediated cell adhesion have been isolated from platelets and metastatic tumor cells. Furthermore, LN fragment serum levels have been found to be elevated in patients with hepatic fibrosis, alcoholic liver, hypertension and several tumor types.
The Laminin EIA Kit is a 96-well in vitro assay intended for the quantification of human basal laminal glycoprotein in serum, plasma, urine, cultured cell extract, cell culture supernatants and other biological fluids. It is a solid-phase sandwich laminin ELISA that utilizes two specific mouse monoclonal laminin antibodies, one of which is coated on the plate, and the other of which is peroxidase-labeled. Detection of LN occurs via a two-step incubation method: In the first step, experimental samples are incubated in the antibody-coated microtiter plate. During the second step, the plate is washed and incubated with the peroxidase-labeled LN antibody. A substrate is added (H2O2, TMBZ), and the reaction between the peroxidase and substrate results in the development of color. Sample LN levels are determined by measuring their absorbances on an EIA plate reader. Accurate LN sample concentrations can be determined by comparing their specific absorbances against the absorbance of the standard (using a generated standard curve).